Case report demonstrates clinical remission in an adolescent with eosinophilic fasciitis using combination therapy, suggesting novel treatment avenues.
Eosinophilic fasciitis (EF) and morphea are rare sclerosing connective tissue disorders, and there remains debate about whether these entities are pathologically distinct or related. This case report describes the successful treatment of an adolescent patient who developed progressive morphea plaques while being treated with systemic corticosteroids, intravenous immunoglobulin, and methotrexate for EF. A novel combination of topical tofacitinib, a Janus kinase (JAK) inhibitor, and UVA-1 phototherapy induced clinical remission and was well tolerated, warranting further investigation into such combination therapy.
No takes yet. Share an insight, caveat, or question.
Cheung et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: